Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series. — CFSMEATLAS
Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series.
Gil, Anna, Hoag, George E, Salerno, John P et al. · Brain, behavior, & immunity - health · 2024 · DOI
Quick Summary
This study found that people with ME/CFS and Long COVID have immune cells (called CD8 T-cells) that don't work properly—they can't produce certain protective substances as well as healthy people can. The researchers also tested a nebulized (inhaled) treatment made from five natural antioxidant ingredients in a small group of patients and found that both the immune cell function and symptom severity improved over time with treatment, without serious side effects.
Why It Matters
This research identifies CD8 T-cell dysfunction as a potential shared biological marker for both ME/CFS and Long COVID, which could improve diagnosis and disease tracking. The preliminary evidence suggesting a novel nebulized treatment may improve both immune function and symptoms could open new therapeutic avenues for these disabling conditions that currently lack approved treatments.
Observed Findings
CD8 T-cells from ME/CFS and Long COVID patients produced significantly lower levels of IFNγ and TNFα compared to healthy controls after stimulation
Both ME/CFS and Long COVID patients reported similar symptom profiles on severity questionnaires
In 8 patients treated with nebulized antioxidant/anti-pathogen agent, CD8 T-cell IFNγ and TNFα production increased over 3-15 months
Self-reported symptom severity decreased by 54% in the treated patient group
No serious treatment-associated side effects or laboratory abnormalities were reported during treatment
Inferred Conclusions
CD8 T-cell dysfunction characterized by impaired cytokine production may be a shared pathogenic feature of both ME/CFS and Long COVID
A nebulized antioxidant/anti-pathogen treatment may improve immune dysfunction and clinical symptoms in these conditions
CD8 T-cell function could serve as a useful biomarker for diagnosis and monitoring treatment response in clinical trials
Oxidative stress and immune dysregulation may be targetable therapeutic pathways in both ME/CFS and Long COVID
Remaining Questions
Does CD8 T-cell dysfunction cause the symptoms of ME/CFS and Long COVID, or is it a consequence of other disease processes?
What This Study Does Not Prove
This study does not prove that the nebulized treatment causes symptom improvement—the retrospective design without a control group cannot establish causation. The small sample size and lack of blinding mean results may not be reproducible or generalizable. It also does not prove that CD8 T-cell dysfunction is the primary cause of ME/CFS or Long COVID, only that it is associated with these conditions.